Indian's Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa

India's largest drugmaker, Ranbaxy Laboratories (which is 64% owned by Japanese drug major Daiichi Sanko), has announced the opening of its new state-of-the-art manufacturing facility, Be-Tabs Pharmaceuticals Manufacturing Plant, at Roodepoort, Johannesburg, South Africa.

The new facility, built with an investment of $30 million, will manufacture analgesics, cold, cough and flu preparations, anti-histamines, anti-hypertensives, central nervous system drugs, vitamins and minerals, as well as a comprehensive range of over-the-counter medicines. The products manufactured will comprise tablets and hard gelatin capsules that will be supplied to current registered regions. This will be Ranbaxy's second manufacturing facility in South Africa and the third in the African continent.